Mode
Text Size
Log in / Sign up
N/A N=184 Randomized Double-blind Supportive Care

Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)

Post-Operative Nausea and Vomiting · Breast Cancer

Enrolled (actual)
184
Serious AEs
0.0%
Results posted
Dec 2025
Primary outcome: Primary: Efficacy of Intervention to Prevent Post-Operative Nausea and Vomiting (PONV) — 19; 12; 67; 71 Participants — p=0.2787

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Electrical Stimulation (Procedure); Zofran (Drug); Dexamethasone (Drug); Phenergan (Drug); Pepcid (Drug); Questionnaire (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
M.D. Anderson Cancer Center
Primary completion
Nov 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Efficacy of Intervention to Prevent Post-Operative Nausea and Vomiting (PONV)
19; 12; 67; 71; 0; 3 0.2787
SECONDARY
Feasibility of Conducting Study
233; 188; 86
SECONDARY
Efficacy of Intervention to Prevent Need for Rescue Anti-emetics
45; 54; 14; 11; 45; 54
SECONDARY
Satisfaction
8.92; 9.25 0.8252
SECONDARY
Efficacy of Intervention to Result in Decreased PACU Length-of-stay
120; 119.46 0.8277
SECONDARY
Expectancy
13; 8; 14; 18; 45; 37 0.3908
SECONDARY
Expectancy and Response to P6 Stimulation
6; 15; 6; 25; 9; 72 0.2742

Summary

The goal of this clinical research study is to learn if light electrical stimulation to the wrist area during surgery is feasible in women having breast surgery.

Eligibility Criteria

Inclusion Criteria

  • Adults at least 18 years of age
  • Female gender
  • History of patient reported PONV, CINV or motion sickness
  • Patients scheduled for Breast Surgery
  • Sign an informed consent indicating they are aware of the investigational nature of this study.

Exclusion Criteria

  • Patients scheduled for paravertebral block
  • Upper extremity deformity contralateral to the site of disease that could interfere with accurate point location or alter the energy pathway as defined by traditional acupuncture theory
  • Local skin infections at or near the acustimulation site
  • Pre-existing nausea and vomiting, defined as nausea or vomiting requiring pharmacological treatment greater than 3 times in the week preceding screening
  • History of CVA or other central nervous system disorder resulting in residual weakness or paresis of extremity contralateral to the site of disease
  • Grade III or IV upper extremity peripheral neuropathy
  • Cardiac pacemakers. Patients involved in this protocol will receive electrical stimulation. For safety reasons, electrical stimulation should be avoided in patients with pacemakers
  • Metal implants for the treatment extremity. For safety reasons, use of electrical stimulation should be avoided
  • Current acknowledged use of any illicit drugs, medical marijuana (including Marinol), or evidence of alcohol abuse as defined by The American Psychiatric Association criteria. This includes patients who are currently in the recovery process.
  • Pregnancy as this would alter anesthesia plan
  • Bowel obstruction
  • Surgery that would not allow access to at least one P6 site.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02473042). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search